■目前,关于医学的未来有很多讨论。从研究和开发到监管部门批准和获得患者,直到医药产品从市场撤出,有许多挑战和许多障碍需要克服。并行,商业环境变化迅速。所以,最大的问题是制药生态系统在未来将如何发展。
■回顾了有关最新商业和科学发展与趋势的最新文献。
■在商业环境中,互联网和物联网的发展带来了巨大的变化。一种新的生产方法出现在一个称为知识共享的框架中;生产者和消费者可以在同一过程的背景下逐步确定。随着技术的快速发展,它由人工智能(AI)主导,它的子集,机器学习,以及使用大数据和真实世界数据(RWD)来产生真实世界证据(RWE)。纳米技术是一个跨科学领域,为制造尺寸为十亿分之一米的设备和产品提供了新的机会。人工神经网络和深度学习(DL)正在模仿人类大脑的使用,将计算机科学与复杂系统的新理论基础相结合。这些演进的实施已经在医药产品的生命周期中开始,包括筛选候选药物,临床试验,药物警戒(PV),营销授权,制造,和供应链。这已经成为一个新的生态系统,其特点是免费的在线工具和在线可用的免费数据。个性化医疗是一个突破性的领域,可以为每个患者的基因组提供量身定制的治疗解决方案。
■随着制药生态系统和技术的快速发展,各种互动发生。这可以导致更好的,更安全,更有效的治疗方法开发得更快,更可靠,数据驱动和证据具体方法,这将为患者带来好处。
UNASSIGNED: Currently, there is a lot of discussion about the future of medicine. From research and development to regulatory approval and access to patients until the withdrawal of a medicinal product from the market, there have been many challenges and a lot of barriers to overcome. In parallel, the business environment changes rapidly. So, the big question is how the pharma ecosystem will evolve in the future.
UNASSIGNED: The current literature about the latest business and scientific evolutions and trends was reviewed.
UNASSIGNED: In the business environment, vast changes have taken place via the development of the internet as well as the Internet of Things. A new approach to production has emerged in a frame called Creative Commons; producer and consumer may be gradually identified in the context of the same process. As technology rapidly evolves, it is dominated by Artificial Intelligence (AI), its subset, Machine Learning, and the use of Big Data and Real-World Data (RWD) to produce Real-World Evidence (RWE). Nanotechnology is an inter-science field that gives new opportunities for the manufacturing of devices and products that have dimensions of a billionth of a meter. Artificial Neural Networks and Deep Learning (DL) are mimicking the use of the human brain, combining computer science with new theoretical foundations for complex systems. The implementation of these evolutions has already been initiated in the medicinal products\' lifecycle, including screening of drug candidates, clinical trials, pharmacovigilance (PV), marketing authorization, manufacturing, and the supply chain. This has emerged as a new ecosystem which features characteristics such as free online tools and free data available online. Personalized medicine is a breakthrough field where tailor-made therapeutic solutions can be provided customized to the genome of each patient.
UNASSIGNED: Various interactions take place as the pharma ecosystem and technology rapidly evolve. This can lead to better, safer, and more effective treatments that are developed faster and with a more solid, data-driven and evidence-concrete approach, which will drive the benefit for the patient.